The Q2 beat and raised guidance are positive, but the company's $14M market cap and going-concern risk mean execution risk is extreme. Monitor for the final MolDX coverage determination and Q3 2026 results to validate the growth trajectory toward EBITDA break-even.
Price Chart
Executive Summary
Bionano Genomics presented an investor deck at the H.C. Wainwright conference, highlighting Q2 2026 revenue of $8.2M (above guidance of $7.5-$7.8M), a raised FY2026 guidance range to $31-$33M, and a long-range plan projecting EBITDA break-even by Q4 FY27. The presentation also noted the retirement of JGB debt and progress on Medicare coverage for its OGM technology. While the Q2 beat and raised guidance are positive, the company remains pre-profitability with a $14M market cap and a history of going-concern disclosures, tempering the bullish signal.
Key Facts
- Q2 2026 revenue of $8.2M beat guidance of $7.5-$7.8M.
- FY2026 revenue guidance raised to $31-$33M from $30-$33M.
- Q2 2026 adjusted gross margin of 53%, up 116 bps YoY.
- JGB debt retired, which was secured by $10.3M in restricted cash.
- FY27 revenue projected at $50-$54M, with ~$0 adjusted EBITDA exit rate in Q4 FY27.
- MolDX local coverage determination for OGM in hematologic malignancies published for public comment on August 27, 2026.
- The company has a going-concern risk and requires additional financing to fund operations.
Financial Impact
Q2 2026 revenue of $8.2M beat guidance; FY26 guidance raised to $31-$33M; FY27 revenue projected at $50-$54M.
Risk Factors
- Going-concern risk requiring additional financing.
- Dependence on MolDX Medicare coverage determination for revenue growth.
- Small market cap ($14M) amplifies stock volatility.
- Long-range plan projections are aspirational and may not materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001411690-26-000046 |
| Document: bngo-ex99_1.htm | 0001411690-26-000046 |
| Document: 0001411690-26-000046-index-headers.html | 0001411690-26-000046 |
| Document: 0001411690-26-000046-index.html | 0001411690-26-000046 |
| Document: 0001411690-26-000046.txt | 0001411690-26-000046 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $1.22 $1.16 | ▼ −4.92% | ▼ −4.77% | $1.16 (−4.92%) |
Sep 14, 2026 6w ago | Press Release | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.16 (−12.78%) |
Sep 14, 2026 6w ago | 8-K | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.16 (−12.78%) |
Aug 10, 2026 11w ago | 8-K | $1.19 $1.18 | ▼ −0.84% | ▼ −0.44% | $1.16 (−2.52%) |
Jun 5, 2026 20w ago | 8-K | $1.17 $1.16 | ▲ +0.85% | ▲ +2.97% | $1.16 (+0.85%) |
May 28, 2026 21w ago | 8-K | $1.25 $1.30 | ▲ +4.00% | ▲ +4.05% | $1.16 (−7.20%) |
Mar 23, 2026 31w ago | Press Release | $1.18 $1.17 | ▲ +0.85% | ▲ +0.42% | $1.16 (+1.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers